- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00860691
Double Blinded Randomized Clinical Trial of the Effect of Open Versus Laparoscopic Colectomy on Neutrophils in Patients With Colon Cancer
The purpose of this study is:
- to determine neutrophil activity in patients with colon cancer,
- to determine levels sFas, sFasL and IL - 17 in serum of healthy volunteers and colon cancer patients and establish its prognostic value,
- to elucidate the relationship between serum sFas, sFasL and IL - 17 levels and clinicopathologic features of colon cancer,
- to compare the influence of laparoscopic and conventional procedures on postoperative serum sFas and sFasL levels in colon cancer patients
- to compare the influence of laparoscopic and conventional procedures on postoperative serum IL - 17 levels in colon cancer patients
- to compare the influence of laparoscopic and conventional procedures on postoperative neutrophil functions
- to confirm the expression of FasL protein in human colorectal cancer and elucidate the relationship between FasL expression and clinicopathologic features of the disease, to establish the prevalence of Fas in primary colon adenocarcinomas and elucidate the relationship between FasL expression and clinicopathologic features of the disease
- to determine the functional activity of tumour infiltrating neutrophils
Study Overview
Status
Conditions
Detailed Description
Colorectal cancer is the leading cause of death worldwide. Tumour cell extravasation plays a key role in tumour metastasis. There are evidences tumour cell-leukocyte interactions may support tumour cell invasion and could create an optimal microenvironment for tumour growth at the metastatic site. Neutrophils produce free radicals and proteases; they could cause tumour cytolysis, as well as promote tumour growth and metastasis. It seems that neutrophils play an important role in the context of tumour and angiogenesis.
It is not well understood why FasL induces immune privilege in some organs but elicits inflammation. To explain these apparently conflicting phenomena, it is important to investigate the mechanism of FasL-induced inflammation in detail. Fas/FasL can serve as potential targets for effective antitumor therapy. This research will be useful to eludicate the importance of neutrophil in colorectal cancer. We will investigate the possible role of neutrophil activity and FasL-induced neutrophil infiltration on tumor growth in colorectal cancer. sFas and sFasL could be a way to measure the balance of apoptotic and immunoescape effect after surgical resection of colon cancer.
If the number of neutrophils in peripheral blood mirrors the situation in the tumor tissue, these data could support the investigation of neutrophil-targeted therapies in anti-cancer strategy.
Inflammation-dependent angiogenesis seems to be a central force in tumor growth and expansion, a concept supported by the observation that the use of anti-inflammatory drugs, leads to angiogenesis inhibition. The mechanisms of inflammatory angiogenesis could provide new approaches to target, cure, or prevent tumor angiogenesis. Investigation of the physiologic regulation of IL-17 may thus be useful for the treatment in clinical settings characterized by persistent neovascularisation.
Inhibition of neutrophil elastase might not only reduce the inflammatory response, but could also prevent cancer cell progression. Anti-neutrophil elastase therapy after tumour resection might be an important strategic approach for managing postoperative complications and preventing cancer recurrence.
Patients will be allocated to laparoscopic or conventional open colorectal surgery after eligibility had been confirmed and informed consent given. Randomization will be performed by computer; sequencing was based on a list of variable block sizes for a single centre without further stratification. The randomization list and opaque envelopes will be generated by independent personnel not otherwise involved in the trial. Information on the operation will be remain in consecutively numbered and sealed envelopes that will be stored in a specific box at the clinical site. The envelope containing the allocation will be added to a patient's file shortly before he or she enter the operating theatre. The envelope will be then open and the surgeon will perform the assigned procedure. Until the day of discharge of participants, nurses and other medical staff will be blinded for the type of surgery performed in patients with colorectal cancer by applying a covering abdominal bandage.
During the trial, all blood samples will be retrieved and assessed by a cytologist and molecular biologist blinded to the study arms.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Igor Stipancic, MD, PhD, Professor
- Phone Number: +3851290 2517
- Email: igors@kbd.hr
Study Contact Backup
- Name: Valentina Ratkajec, MD
- Phone Number: +3851290 3612
- Email: vratkajec@kbd.hr
Study Locations
-
-
-
Zagreb, Croatia, 10 000
- Recruiting
- University Hospital "Dubrava"
-
Contact:
- Igor Stipancic, MD, PhD, Professor
- Phone Number: +3851290 2517
- Email: igors@kbd.hr
-
Contact:
- Valentina Ratkajec, MD
- Phone Number: +3851290 3612
- Email: vratkajec@kbd.hr
-
Principal Investigator:
- Valentina Ratkajec, MD
-
Sub-Investigator:
- Igor Stipancic, MD, PhD, Professor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All patients will be informed that additional blood and tissue samples will be taken during perioperative period for colon cancer research, and written consent will be obtained. Informed consent will be also obtained from each healthy volunteer.
Patients with the clinical diagnosis of colorectal cancer based on colonoscopy following histological confirmation will recruited. They should be suitable for elective surgical resection of the tumour along with lymph node dissection by right and left hemicolectomy, sigmoid colectomy, and anterior resection. Clinicopathologic characteristics of these patients will be investigated based on TNM classification of malignant tumours and modified Dukes classification Inclusion criteria; age between 18 and 80 years; colorectal cancer with single tumour locating at cecum, ascending colon, descending colon, sigmoid colon or recto sigmoid junction (distance from anal verge more than 15 cm); ASA I-III; and informed consent.
Exclusion criteria; patient refusal to participate in the prospective data collection; prior midline laparotomy; emergency surgery or urgent operation within 24 h after admission to the hospital; conversion to laparotomy; mechanic ileus; perforation or abscess with septic inflammatory response syndrome; planned stoma, low anterior resection or rectal extirpation; known immunological dysfunction (human immunodeficiency virus infection); presence of ongoing infection or infective chronic diseases; severe cardiovascular disease (New York Heart Association class higher than 3) or pulmonary insufficiency (severe pulmonary emphysema, interstitial pneumonitis, arterial PO2<79 mmHg); advanced liver disease (Child-Pugh class C); synchronous or metachronous (within five years) malignancy; pregnant or lactating women; continuous systemic steroid therapy; drug addiction; previous chemotherapy, radiotherapy or immune therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ARM I - Open colorectal surgery
Open colorectal surgery
|
Patients with colorectal cancer undergo open laparotomy and colorectal resection
Other Names:
|
Experimental: ARM II - Laparoscopic colorectal surgery
Laparoscopic colorectal surgery
|
Patients with colorectal cancer undergo laparoscopic colorectal resection
|
Other: Control - reference value
Blood samples from healthy volunteers will be obtained at one time point.Peripheral blood samples will be obtained into tubes with no additive (BD Vacutainer System, Plymouth, UK).Samples will be processed to serum.
Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA)using specific anti-Fas MoAbs, Human sFas Immunoassay.
Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay.
Serum concentration of IL - 17 will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using Human IL-17 Immunoassay. .
Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.
burst neutrophil production will be determined quantitatively by flow cytometry as described by Rothe using a commercial kit Bursttest Kit.
|
Informed consent will be obtained.Blood samples will be obtained at one time point.
.Samples will be processed to serum, using a refrigerated centrifuge, then stored at -80C until analysis.
Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fas MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA).
Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA).Respiratory burst neutrophil production will be determined quantitatively by flow cytometry using a commercial kit Bursttest Kit (Cat.
No: 10-0200; ORPEGEN Pharma, Germany)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Neutrophil activity before and after the open or laparoscopic surgery - Serum concentrations of sFas, sFasL and IL - 17.
Time Frame: 24 hours before surgery, 72 hours after surgery
|
24 hours before surgery, 72 hours after surgery
|
Respiratory burst neutrophil production - Bursttest before and after open or laparoscopic surgery
Time Frame: 24 hours before surgery and 2 hours after surgery
|
24 hours before surgery and 2 hours after surgery
|
Immunohistochemical detection of FasL in tumor and paratumor areas of colon cancer and normal colon mucosa taken at a distance of 10 cm from the tumor
Time Frame: after surgery
|
after surgery
|
Immunohistochemical detection of Fas in tumor and paratumor areas of colon cancer and normal colon mucosa taken at a distance of 10 cm from the tumor
Time Frame: after surgery
|
after surgery
|
Immunohistochemical detection of neutrophil elastase in tumor and paratumor areas of colon cancer and normal colon mucosa taken at a distance of 10 cm from the tumor
Time Frame: after surgery
|
after surgery
|
Number of leukocytes, neutrophils, lymphocytes and neutrophils/lymphocytes ratio
Time Frame: 24 hours before surgery, 2 hours after surgery, 72 hours after surgery
|
24 hours before surgery, 2 hours after surgery, 72 hours after surgery
|
CRP
Time Frame: 24 hours before surgery, 72 hours after surgery
|
24 hours before surgery, 72 hours after surgery
|
Fe, transferrin, ferritin
Time Frame: 24 hours before surgery, 72 hours after surgery
|
24 hours before surgery, 72 hours after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
to determine neutrophil activity in patients with colon cancer and healthy volunteers
Time Frame: 24 hours before surgery, 2 hours and 72 hours after surgery
|
24 hours before surgery, 2 hours and 72 hours after surgery
|
to compare the influence of laparoscopic and conventional procedures on postoperative neutrophil function
Time Frame: 24 hours before surgery, 2 hours and 72 hours after surgery
|
24 hours before surgery, 2 hours and 72 hours after surgery
|
to determine functional activity of tumour infiltrating neutrophils
Time Frame: after surgery
|
after surgery
|
to determine an effect of surgery on neutrophil activity
Time Frame: 24 hours before surgery, 2 hours and 72 hours after surgery
|
24 hours before surgery, 2 hours and 72 hours after surgery
|
to determine levels sFas, sFasL and IL - 17 in serum of healthy volunteers and colon cancer patients and establish its prognostic value
Time Frame: 24 hours before surgery, 2 hours and 72 hours after surgery
|
24 hours before surgery, 2 hours and 72 hours after surgery
|
to eludicate the relationship between serum sFas, sFasL and IL - 17 levels and clinicopathologic features of colon cancer
Time Frame: 24 hours before surgery, 2 hours and 72 hours after surgery
|
24 hours before surgery, 2 hours and 72 hours after surgery
|
to compare the influence of laparoscopic and conventional procedures on postoperative serum sFas, sFasL and IL - 17 levels in colon cancer patients
Time Frame: 24 hours before surgery, 2 hours and 72 hours after surgery
|
24 hours before surgery, 2 hours and 72 hours after surgery
|
to confirm the expression of FasL protein in human colorectal cancer and elucidate the relationship between FasL expression and clinicopathologic features of the disease
Time Frame: after surgery
|
after surgery
|
to establish the prevalence of Fas in primary colon adenocarcinomas and elucidate the relationship between Fas expression and clinicopathologic features of the disease
Time Frame: after surgery
|
after surgery
|
loss of blood during the surgery, postoperative hospital stay, morbidity, and mortality within 30 days after surgery
Time Frame: intraoperative and within 30 days after surgery
|
intraoperative and within 30 days after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Igor Stipančić, MD, PhD, Profssor, University Hospital Dubrava
- Principal Investigator: Valentina Ratkajec, MD, University Hospital Dubrava
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 198-0000000-3104
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colonic Neoplasms
-
Imperial College LondonCompletedColonic Diseases | Colonic Polyp | Colonic Neoplasms | Colonic Cancer | Colonic Adenocarcinoma | Colonic Adenoma | Colonic Carcinoma | Colonic Dysplasia | Colon Hyperplastic PolypUnited Kingdom
-
Hospital Universitario de MóstolesCompletedColonic Polyp | Colonic Neoplasms | Colonic Cancer
-
Changi General HospitalNational University Hospital, Singapore; Singapore General Hospital; Tan Tock...CompletedColonic Polyp | Colonic Neoplasms | Colonic DysplasiaSingapore
-
Oxford University Hospitals NHS TrustCompletedRectal Cancer | Ulcerative Colitis | Colonic Cancer | Colonic DiverticulumUnited Kingdom
-
Institute of Gastroenterology and Advance EndoscopyNot yet recruitingColonic Polyp | Colonic Neoplasms | Colonic Adenoma | Colonic DiseaseArgentina
-
The University of Hong KongRecruitingColonic Polyp | Colonic Cancer | Colonic AdenomaHong Kong
-
University of Turin, ItalyNot yet recruitingColonic Polyp | Colonic Neoplasms | Colonic Dysplasia
-
The University of Hong KongUnknownColonic Polyps | Colonic CancersHong Kong
-
UNC Lineberger Comprehensive Cancer CenterPfizer; AmgenActive, not recruitingColon Cancer | Colonic Cancer | Cancer of the Colon | Colon Neoplasms | Neoplasms, ColonicUnited States
-
Chinese University of Hong KongCompleted
Clinical Trials on Therapeutic conventional colorectal surgery
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedSkin Basal Cell CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnAdult Spinal Cord Neoplasm | Spinal Bone Metastases | Spinal Cord Metastases
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC; AIDS and Cancer Specimen ResourceActive, not recruitingHIV Infection | Anal Squamous Cell Carcinoma | Stage 0 Anal Canal Cancer | Stage I Anal Canal CancerUnited States
-
University of California, DavisNational Cancer Institute (NCI)CompletedPain | Breast Cancer | Perioperative/Postoperative ComplicationsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)UnknownBreast CancerUnited States
-
Roei Medical Technologies Ltd.Completed
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingBladder CancerUnited States, Canada
-
Institute of Cancer Research, United KingdomCompletedBladder CancerUnited Kingdom
-
Duke UniversityNational Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBreast CancerUnited States